Avelumab in combination with axitinib [AVE3]

For use in treatment-naïve patients with advanced, favourable risk, renal cell carcinoma where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anti-cancer therapy with the combination of avelumab and axitinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
2. The patient has unresectable locally advanced or metastatic renal cell carcinoma (RCC) which has either a clear cell component or is one of the types of RCC as indicated below. Please indicate below which RCC histology applies to this patient:

• RCC with a clear cell component or
• Papillary RCC or
• Chromophobe RCC or
• Collecting duct RCC (Bellini collecting duct RCC) or
• Medullary RCC or
• Mucinous tubular and spindle cell RCC or
• Multilocular cystic RCC or
• XP11 translocation RCC or
• Unclassified RCC

3. The prescribing clinician confirms that the risk status as assessed by the International Metastatic RCC Database Consortium (IMDC) system for this patient is FAVOURABLE-RISK (i.e. no risk factors present, and therefore an IMDC score of zero)

Note

Note: The combination of avelumab and axitinib CANNOT be used for patients who have an IMDC risk status of intermediate or poor.

4. The patient is either completely treatment naïve for systemic immune-modulatory therapy for RCC or if the patient has received prior systemic immune-modulatory therapy in the context of adjuvant/neoadjuvant therapy, then such treatment was completed 12 or more months previously and the patient meets all other criteria listed here. Please mark below whether or not previous systemic immune-modulatory therapy has been received in the adjuvant/neoadjuvant setting:

• no previous adjuvant/neoadjuvant systemic immune-modulatory therapy of any kind and the patient is treatment naïve for the locally advanced/metastatic RCC indication or
• prior adjuvant/neoadjuvant therapy with immune-modulatory therapies for RCC anti-Programmed Death receptor-1 (PD-1), anti-Programmed Death-1 ligand-1 (PD-L1), anti-PD L2, anti-CD137 or anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) antibodies and last dose received by the patient was 12 or more months prior to this application and the patient is treatment-naïve for the locally advanced/metastatic RCC indication Please mark in the box the time since end of treatment with adjuvant/neoadjuvant immune-modulatory therapy: _________

5. The patient has an ECOG performance status of 0 or 1.
6. The patient has no symptomatic brain metastases or leptomeningeal metastases currently requiring steroids for symptom control.
7. The patient is to be treated until loss of clinical benefit or excessive toxicity or patient choice, whichever is the sooner.

Note

Note: there is no stopping rule as to the maximum treatment duration of avelumab plus axitinib in this indication. Note: if either avelumab or axitinib has to be permanently discontinued on account of toxicity, treatment with the other drug can be continued as monotherapy as long as there is no evidence of progressive disease.

8. Avelumab and axitinib will otherwise be prescribed and administered as outlined in their respective Summary of Product Characteristics (SPCs).
9. When a treatment break of more than 12 weeks beyond the expected 4-weekly cycle length is needed, the prescribing clinician will complete a treatment break approval form to restart treatment, which MUST be approved before treatment is recommenced.
10. If the disease progresses on the avelumab and axitinib combination and further systemic therapy is appropriate, the next line of treatment will be chosen from those options which are routinely commissioned ie for the next line of systemic therapy, there will be use of one choice of the following (mainly incorporating TKI options which have multiple modes of action [so-called ‘dirty’ TKIs)]: the currently commissioned 2nd line options of cabozantinib or lenvatinib plus everolimus or everolimus monotherapy or the currently commissioned 1st line options of sunitinib (still on label as 2nd line treatment) or pazopanib (off label as 2nd line treatment, or tivozanib (off-label as 2nd line treatment).

NHS funded From: 07 February 2026

Additional information

Form version: -

CDF Managed Access: NA

NICE Technology Appraisal: TA1120 (08 January 2026)

Current Form Version

Note

The data on this page was produced using version 1.386 of the CDF list, downloaded from NHS England’s website on 12 February 2026 at 18:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.

• AVE3_prior_to_cdf_1.361
• AVE3_prior_to_cdf_1.380
• AVE3_prior_to_cdf_1.386